ASMB Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Assembly Biosciences, Inc. had $72.3M of revenue in fiscal 2025, up 153.5% on the year before. Over five years, revenue changed β1.8% a year on average.
Last close Β· Oct 23, 2026
$19.84
2.2%Hi! I read Assembly Biosciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+153.5%
Yes. Sales grew 153.5% last year.
Does it make a profit?
β8.5%
No. It lost money last year.
Does profit turn into cash?
β56.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
16.4x
One share costs 16.4 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Assembly Biosciences, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 14 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 19, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 10, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 8, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 20, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Assembly Biosciences, Inc. had $72.3M of revenue in fiscal 2025, up 153.5% on the year before. Over five years, revenue changed β1.8% a year on average. Its operating margin was β16.8%, up 142.5Β pts: of every 100 in sales, about β17 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Assembly Biosciences, Inc. lost $6.1M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$41.2M in fiscal 2025, β56.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Assembly Biosciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $147M | $91.6M | $130M | $112M | $248M |
| Current ratio | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Quick ratio | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Total assets | $191M | $102M | $137M | $119M | $258M |
| Total liabilities | $22.1M | $19.1M | $95.7M | $85.8M | $50.8M |
| Shareholders' equity | $169M | $82.7M | $41.1M | $33.4M | $207M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Assembly Biosciences, Inc. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 7 | 3 / 7 | 2 / 7 | 2 / 7 | 2 / 7 | 2 / 7 | 4 / 7 | 2 / 7 | 3 / 7 |
| Accruals ratio | β9.6% | β33.4% | β11.8% | β4.5% | 0.3% | β15.4% | β5.9% | β70.4% | 8.5% | 18.6% |
| Altman Z'' | β2.32 | β0.55 | 2.37 | 3.04 | 3.24 | β2.68 | β19.68 | β16.91 | β21.02 | β1.34 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $9.0M | $14.8M | $16.0M | $79.1M | $6.3M | $0.0M | $7.2M | $28.5M | $72.3M |
| Research and development | $33.1M | $44.2M | $72.7M | $85.8M | $107M | $68.5M | $70.0M | $48.9M | $55.9M | $64.8M |
| Operating income | β$45.3M | β$52.2M | β$92.7M | β$103M | β$64.8M | β$133M | β$94.1M | β$64.6M | β$45.4M | β$12.1M |
| Pretax income | β$44.9M | β$51.9M | β$89.7M | β$98.4M | β$62.2M | β$132M | β$93.1M | β$61.2M | β$39.8M | β$6.1M |
| Income tax | β$0.6M | β$9.1M | $1.1M | β$0.8M | $0.0M | β$2.5M | $0.0M | $0.0M | $0.3M | $0.0M |
| Net income | β$44.3M | β$42.8M | β$90.8M | β$97.6M | β$62.2M | β$130M | β$93.1M | β$61.2M | β$40.2M | β$6.1M |
| Diluted EPS | β$2.57 | β$2.41 | β$3.98 | β$3.72 | β$1.75 | β$3.00 | β$23.08 | β$13.38 | β$6.69 | β$0.55 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.03B | 0.04B | 0.04B | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$34.9M | $1.9M | β$65.0M | β$84.1M | β$63.0M | β$93.4M | β$84.5M | $22.7M | β$51.1M | β$41.1M |
| Capital expenditure | $0.1M | $0.9M | $0.3M | $1.6M | $0.5M | $3.1M | $0.1M | $0.3M | $0.0M | $0.1M |
| Free cash flow | β$35.0M | $1.0M | β$65.3M | β$85.6M | β$63.4M | β$96.5M | β$84.6M | $22.5M | β$51.1M | β$41.2M |
| Depreciation and amortization | $0.1M | $0.2M | $0.6M | $0.5M | $0.7M | $0.5M | $0.5M | $0.5M | $0.1M | $0.1M |
| Stock-based compensation | $5.0M | $8.6M | $28.5M | $20.6M | $21.9M | $5.2M | $6.6M | $5.1M | $3.1M | $4.7M |
| Acquisitions | $0.0M | β | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $53.0M | $120M | $218M | $274M | $216M | $147M | $91.6M | $130M | $112M | $248M |
| Current assets | $53.6M | $123M | $223M | $283M | $224M | $154M | $97.0M | $134M | $116M | $255M |
| Current liabilities | $7.1M | $13.5M | $18.5M | $24.4M | $24.4M | $16.1M | $16.3M | $39.2M | $47.8M | $48.8M |
| Property and equipment, net | $0.2M | $0.9M | $0.6M | $1.8M | $1.6M | $1.1M | $0.7M | $0.4M | $0.3M | $0.2M |
| Goodwill | $12.6M | $12.6M | $12.6M | $12.6M | $12.6M | β | β | β | β | β |
| Intangible assets | $29.0M | $29.0M | β | β | β | β | β | β | β | β |
| Total assets | $98.1M | $169M | $268M | $340M | $283M | $191M | $102M | $137M | $119M | $258M |
| Total liabilities | $18.2M | $56.2M | $57.4M | $66.7M | $42.7M | $22.1M | $19.1M | $95.7M | $85.8M | $50.8M |
| Preferred stock | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Shareholders' equity | $79.9M | $113M | $211M | $273M | $241M | $169M | $82.7M | $41.1M | $33.4M | $207M |
| Margins | ||||||||||
| Operating margin | β | β579.1% | β626.4% | β643.4% | β81.9% | β2,121.7% | β | β902.5% | β159.3% | β16.8% |
| EBITDA margin | β | β576.6% | β622.1% | β640.3% | β81.0% | β2,114.2% | β | β896.2% | β158.8% | β16.6% |
| Net margin | β | β474.7% | β613.0% | β611.6% | β78.6% | β2,076.4% | β | β854.8% | β140.9% | β8.5% |
| FCF margin | β | 11.0% | β441.1% | β536.4% | β80.2% | β1,542.9% | β | 313.9% | β179.3% | β56.9% |
| Returns | ||||||||||
| Return on capital employed | β49.8% | β33.5% | β37.2% | β32.6% | β25.0% | β75.8% | β110.1% | β66.2% | β63.6% | β5.8% |
| Return on equity | β55.4% | β44.4% | β56.1% | β40.4% | β24.2% | β63.4% | β74.0% | β98.9% | β107.9% | β5.1% |
| Return on assets | β45.1% | β32.0% | β41.5% | β32.1% | β19.9% | β54.8% | β63.6% | β51.3% | β31.4% | β3.2% |
| Return on tangible equity | β115.7% | β59.9% | β45.8% | β37.5% | β27.3% | β76.9% | β112.6% | β149.0% | β120.4% | β3.0% |
| Growth | ||||||||||
| Revenue growth | β | β | 64.1% | 7.8% | 395.6% | β92.1% | β100.0% | β | 298.2% | 153.5% |
| FCF growth | β | β | β6,662.6% | β | β | β | β | β | β327.4% | β |
| Share count change | β | 3.0% | 28.5% | 15.2% | 34.9% | 22.2% | β90.7% | 13.5% | 31.2% | 86.7% |
| Financial health | ||||||||||
| Current ratio | 7.5x | 9.1x | 12.0x | 11.6x | 9.2x | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Quick ratio | 7.5x | 9.1x | 12.0x | 11.6x | 9.2x | 9.6x | 6.0x | 3.4x | 2.4x | 5.2x |
| Capital allocation | ||||||||||
| Capex / revenue | β | 9.6% | 2.3% | 9.7% | 0.6% | 49.5% | β | 3.6% | 0.1% | 0.1% |
| Stock comp / revenue | β | 95.4% | 192.4% | 128.8% | 27.6% | 83.7% | β | 71.5% | 10.9% | 6.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 3.0 | 2.0 | 2.0 | 2.0 | 2.0 | 4.0 | 2.0 | 3.0 |
| Altman Z'' | β2.3 | β0.5 | 2.4 | 3.0 | 3.2 | β2.7 | β19.7 | β16.9 | β21.0 | β1.3 |
| Accruals ratio | β9.6% | β33.4% | β11.8% | β4.5% | 0.3% | β15.4% | β5.9% | β70.4% | 8.5% | 18.6% |
Source: SEC EDGAR XBRL filings (CIK 0001426800). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
